Signaturefd LLC Has $2.15 Million Position in Sanofi (NASDAQ:SNY)

Signaturefd LLC lifted its holdings in Sanofi (NASDAQ:SNY) by 7.6% during the 3rd quarter, HoldingsChannel reports. The fund owned 37,347 shares of the company’s stock after acquiring an additional 2,647 shares during the quarter. Signaturefd LLC’s holdings in Sanofi were worth $2,152,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Boston Partners lifted its position in Sanofi by 0.3% during the first quarter. Boston Partners now owns 13,066,403 shares of the company’s stock worth $635,280,000 after purchasing an additional 33,657 shares during the period. Bank of New York Mellon Corp increased its position in Sanofi by 19.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after purchasing an additional 1,370,232 shares during the period. Barrow Hanley Mewhinney & Strauss LLC increased its position in Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after purchasing an additional 3,164,092 shares during the period. Mondrian Investment Partners LTD increased its position in Sanofi by 43.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after purchasing an additional 1,190,141 shares during the period. Finally, Envestnet Asset Management Inc. increased its position in Sanofi by 8.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after purchasing an additional 246,224 shares during the period. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Performance

Shares of SNY stock opened at $53.26 on Wednesday. Sanofi has a 52 week low of $42.63 and a 52 week high of $58.97. The firm has a 50 day moving average of $56.13 and a 200-day moving average of $51.62. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The company has a market cap of $134.89 billion, a price-to-earnings ratio of 26.76, a price-to-earnings-growth ratio of 1.57 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. During the same period last year, the business earned $0.95 EPS. Sanofi’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, equities analysts forecast that Sanofi will post 4.25 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Argus raised their price objective on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Finally, StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 14th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.